Nevanac 3-Month Safety Study With QID Dosing

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Ketorolac; Ketorolac Tromethamine; Nepafenac; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients of any race or sex ages 10 years or older undergoing cataract extraction with planned implantation of a posterior chamber intraocular lens.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Under 10

• Other protocol-defined exclusion criteria may apply